Native-like HIV-1 envelope trimers of the SOSIP.664 class were shown in 2015 to induce potent autologous Tier-2 neutralizing antibodies in animals, but not the heterologous broadly neutralizing antibody (bNAb) breadth a human vaccine requires. This problem, posed explicitly by Sanders et al. (Science 2015), asks how such trimers can be modified and delivered to elicit neutralization breadth against heterologous Tier-2 viruses in humans, whether sequential or cocktail regimens and germline-precursor priming can steer antibody maturation toward bNAb lineages, what adjuvanting and dosing are needed, and whether the glycan-dependent polyspecific autologous responses these trimers induce are maturable into breadth or are dead-end specificities. As of 2026 the core is open: germline-targeting priming has succeeded in humans for one bNAb class and consistent cross-neutralization has finally been achieved in outbred nonhuman primates, but no trimer-based regimen has elicited heterologous Tier-2 serum neutralization breadth in humans.

Background

HIV-1 enters cells through its envelope glycoprotein (Env), a trimeric spike made of three gp120 and three gp41 subunits. Most antibodies raised against Env fail to neutralize circulating clinical (so-called Tier-2) viruses, because the conserved surfaces that antibodies must hit are concealed by a dense shield of host-derived sugars (the glycan shield), by conformational masking, and by immunodominant decoy epitopes such as the variable V3 loop. During chronic infection, a minority of people eventually develop broadly neutralizing antibodies (bNAbs), which reach conserved epitopes — the CD4 binding site, the V2 apex, the V3-glycan patch, the fusion peptide, and the gp41 membrane-proximal region — but only after years of coevolution, accumulating unusually high numbers of somatic mutations. A central goal of HIV vaccine research is to reproduce such breadth by immunization.

Soluble stabilized trimers of the SOSIP.664 design — engineered with an inter-subunit disulfide bond (SOS), an Ile-to-Pro point mutation that stabilizes the pre-fusion conformation (IP), and a truncated, soluble 664-residue gp140 construct — were the first recombinant immunogens that structurally mimic the native viral spike, including its closed, antibody-inaccessible conformation. Sanders et al. (2015) showed that the BG505 SOSIP.664 trimer reliably elicits in rabbits and macaques potent neutralization of the autologous (same-strain) Tier-2 virus, but essentially no heterologous (cross-strain) Tier-2 neutralization; the elicited antibodies target trimer-specific features such as holes in the glycan shield, and the authors stated that a human vaccine must generate a more broadly neutralizing response. Epitope mapping later showed these autologous responses concentrate on strain-specific glycan holes (missing N-linked glycans at positions 241/289 and 465) and other variable-region features. The open problem is therefore the full rational-design program the source paper set out: redesign the trimer immunogen (stabilize the apex and bNAb epitopes while silencing non-neutralizing decoys such as V3), design regimens (sequential escape-derived variants, clade cocktails, germline-precursor priming) that steer B-cell maturation toward bNAb lineages, optimize adjuvants and dosing for humans, and determine whether the glycan-dependent polyspecific autologous responses are inherently narrow dead ends or can be matured into breadth. Key terms: Tier-2 viruses are primary-isolate pseudoviruses with relatively antibody-resistant envelopes, the standard challenge in neutralization assays (typically TZM-bl reporter-cell assays); an adjuvant is a formulation component that enhances the immune response to the antigen; germline targeting means designing an immunogen that binds the unmutated precursors of known bNAb lineages so those rare B cells are recruited at priming; SOSIP.664 refers to the stabilized soluble trimer built on the BG505 isolate backbone.

Problem Statement

How can native-like HIV-1 envelope immunogens of the SOSIP.664 class and their delivery regimens be designed so that immunization elicits neutralization breadth against heterologous Tier-2 viruses in humans, rather than only autologous Tier-2 responses in animals? Concretely, as posed by Sanders et al. (2015): (1) Can the trimers be modified — e.g., by sequence changes that stabilize the trimer apex and associated bNAb epitopes while reducing the antigenicity of V3 and other immunodistracting epitopes — without destroying the quaternary bNAb footprints, such that breadth is elicited? (2) Can sequential immunization with SOSIP.664 variants based on later-arising (escape-derived) viral sequences, or cocktails of trimers from different clades, drive antibody maturation pathways that recapitulate the breadth arising over years of natural infection? (3) Can priming immunogens in the native-like trimer context be designed to trigger the germline precursors of known bNAb lineages, and what trimer modifications are required to engage those germline B-cell receptors effectively? (4) What adjuvant, dose, and regimen optimizations, in nonhuman primates and humans, raise trimer-elicited binding and neutralization titers to the levels and kinetics required for breadth-inducing vaccine strategies? (5) Are the glycan-dependent, polyspecific autologous responses these trimers elicit capable, after appropriate boosting or antigenic variation, of maturing into broader specificities in humans, or are they dead-end narrow specificities? The single scientific objective uniting these facets is a trimer-based immunization strategy that reproducibly elicits heterologous Tier-2 serum neutralization breadth (bNAbs) in humans. The five numbered facets are the constituent design axes of this single objective: a resolving answer must address all of them, and no subset alone resolves the task. Breadth here means neutralization of multiple heterologous Tier-2 viruses rather than only the autologous virus; a resolving answer must state the heterologous Tier-2 panel and neutralization criterion by which its proposed strategy would be measured.

References

  1. Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA, Ozorowski G, Cupo A, Simonich C, Goo L, Arendt H, Kim HJ, Lee JH, Pugach P, Williams M, Debnath G, Moldt B, van Breemen MJ, Isik G, Medina-Ramírez M, Back JW, Koff WC, Julien JP, Rakasz EG, Seaman MS, Guttman M, Lee KK, Klasse PJ, LaBranche C, Schief WR, Wilson IA, Overbaugh J, Burton DR, Ward AB, Montefiori DC, Dean H, Moore JP. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science 2015;349:aac4223. doi:10.1126/science.aac4223. https://doi.org/10.1126/science.aac4223
  2. de Taeye SW, Ozorowski G, Torrents de la Peña A, Guttman M, Julien JP, van den Kerkhof TL, Burger JA, Pritchard LK, Pugach P, Yasmeen A, Crampton J, Hu J, Bontjer I, Torres JL, Arendt H, DeStefano J, Koff WC, Schuitemaker H, Eggink D, Berkhout B, Dean H, LaBranche C, Crotty S, Crispin M, Montefiori DC, Klasse PJ, Lee KK, Moore JP, Wilson IA, Ward AB, Sanders RW. Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-Neutralizing Epitopes. Cell 2015;163:1702-1715. doi:10.1016/j.cell.2015.11.056. https://doi.org/10.1016/j.cell.2015.11.056
  3. Klasse PJ, Ketas TJ, Cottrell CA, Ozorowski G, Debnath G, Camara D, Francomano E, Pugach P, Ringe RP, LaBranche CC, van Gils MJ, Bricault CA, Barouch DH, Crotty S, Silvestri G, Kasturi S, Pulendran B, Wilson IA, Montefiori DC, Sanders RW, Ward AB, Moore JP. Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques. PLoS Pathogens 2018;14:e1006913. doi:10.1371/journal.ppat.1006913. https://doi.org/10.1371/journal.ppat.1006913
  4. Torrents de la Peña A, de Taeye SW, Sliepen K, LaBranche CC, Burger JA, Schermer EE, Montefiori DC, Moore JP, Klasse PJ, Sanders RW. Immunogenicity in Rabbits of HIV-1 SOSIP Trimers from Clades A, B, and C, Given Individually, Sequentially, or in Combination. Journal of Virology 2018;92:e01957-17. doi:10.1128/jvi.01957-17. https://doi.org/10.1128/jvi.01957-17
  5. Ringe RP, Pugach P, Cottrell CA, LaBranche CC, Seabright GE, Ketas TJ, Ozorowski G, Kumar S, Schorcht A, van Gils MJ, Crispin M, Montefiori DC, Wilson IA, Ward AB, Sanders RW, Klasse PJ, Moore JP. Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes. Journal of Virology 2019;93:e01656-18. doi:10.1128/jvi.01656-18. https://doi.org/10.1128/jvi.01656-18
  6. Schorcht A, Cottrell CA, Pugach P, Ringe RP, Han AX, Allen JD, van den Kerkhof TLGM, Seabright GE, Schermer EE, Ketas TJ, Burger JA, van Schooten J, LaBranche CC, Ozorowski G, de Val N, Bader DLV, Schuitemaker H, Russell CA, Montefiori DC, van Gils MJ, Crispin M, Klasse PJ, Ward AB, Moore JP, Sanders RW. The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization. Journal of Virology 2022;96:e01552-21. doi:10.1128/jvi.01552-21. https://doi.org/10.1128/jvi.01552-21
  7. Hahn WO, Parks KR, Shen M, Ozorowski G, Janes H, Ballweber-Fleming L, Woodward Davis AS, Duplessis C, Tomai M, Dey AK, Sagawa ZK, De Rosa SC, Seese A, Kallur Siddaramaiah L, Stamatatos L, Lee WH, Sewall LM, Karlinsey D, Turner HL, Rubin V, Furth S, MacPhee K, Duff M, Corey L, Keefer MC, Edupuganti S, Frank I, Maenza J, Baden LR, Hyrien O, Sanders RW, Moore JP, Ward AB, Tomaras GD, Montefiori DC, Rouphael N, McElrath MJ. Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies. Journal of Experimental Medicine 2024;221:e20240604. doi:10.1084/jem.20240604. https://doi.org/10.1084/jem.20240604
  8. Caniels TG, Medina-Ramìrez M, Zhang S, Kratochvil S, Xian Y, Koo JH, Derking R, Samsel J, van Schooten J, Pecetta S, Lamperti E, Yuan M, Carrasco MR, Del Moral Sánchez I, Allen JD, Bouhuijs JH, Yasmeen A, Ketas TJ, Snitselaar JL, Bijl TPL, Martin IC, Torres JL, Cupo A, Shirreff L, Rogers K, Mason RD, Roederer M, Greene KM, Gao H, Silva CM, Baken IJL, Tian M, Alt FW, Pulendran B, Seaman MS, Crispin M, van Gils MJ, Montefiori DC, McDermott AB, Villinger FJ, Koup RA, Moore JP, Klasse PJ, Ozorowski G, Batista FD, Wilson IA, Ward AB, Sanders RW. Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site. Science Immunology 2024;9:eadk9550. doi:10.1126/sciimmunol.adk9550. https://doi.org/10.1126/sciimmunol.adk9550
  9. Ramezani-Rad P, Cottrell CA, Marina-Zárate E, Liguori A, Landais E, Torres JL, Myers A, Lee JH, Baboo S, Flynn C, McKenney K, Salcedo E, Zhou X, Kalyuzhniy O, Georgeson E, Phelps N, Lu D, Eskandarzadeh S, Menis S, Kubitz M, Groschel B, Alavi N, Jackson AM, Lee WH, Tran AS, Ben-Akiva E, Kaczmarek Michaels K, Diedrich JK, Enemuo CA, Lewis V, Pradhan A, Kasturi SP, Schiffner T, Steichen JM, Carnathan DG, Himansu S, Yates JR, Paulson JC, Ozorowski G, Irvine DJ, Silvestri G, Sok D, Ward AB, Crotty S, Schief WR. Vaccination with an mRNA-encoded membrane-bound HIV envelope trimer induces neutralizing antibodies in animal models. Science Translational Medicine 2025;17:eadw0721. doi:10.1126/scitranslmed.adw0721. https://doi.org/10.1126/scitranslmed.adw0721
  10. Parks KR, Moodie Z, Allen MA, Yen C, Furch BD, MacPhee KJ, Ozorowski G, Heptinstall J, Hahn WO, Zheng Z, Lu H, Grant S, Domin E, Duff MO, Seese A, Marini-Macouzet C, Ballweber-Fleming L, Lee WH, Cottrell CA, Liguori A, Georgeson E, Alavi N, Kubitz M, Phelps N, Seaton KE, Cohen KW, Anderson MA, Mondal K, Laufer DS, Kublin JG, Ward AB, Hyrien O, De Rosa SC, Himansu S, Leav B, Reuter C, Tomaras GD, Montefiori D, Walsh SR, Frank I, Sobieszczyk ME, Goepfert PA, Stephenson KE, Baden LR, Van Tieu H, Keefer MC, Clark J, Riddler SA, Schief WR, McElrath MJ. Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial. Science Translational Medicine 2025;17:eady6831. doi:10.1126/scitranslmed.ady6831. https://doi.org/10.1126/scitranslmed.ady6831
  11. Caniels TG, Prabhakaran M, Ozorowski G, MacPhee KJ, Wu W, van der Straten K, Agrawal S, Derking R, Reiss EIMM, Millard K, Turroja M, Desrosiers A, Bethony J, Malkin E, Liesdek MH, van der Veen A, Klouwens M, Snitselaar JL, Bouhuijs JH, Bronson R, Jean-Baptiste J, Gajjala S, Rikhtegaran Tehrani Z, Benner A, Ramaswami M, Duff MO, Liu YW, Sato AH, Kim JY, Baken IJL, Mendes Silva C, Bijl TPL, van Rijswijk J, Burger JA, Cupo A, Yasmeen A, Phulera S, Lee WH, Randall KN, Zhang S, Corcoran MM, Regadas I, Sullivan AC, Brown DM, Bohl JA, Greene KM, Gao H, Yates NL, Sawant S, Prins JM, Kootstra NA, Kaminsky SM, Barin B, Rahaman F, Meller M, Philiponis V, Laufer DS, Lombardo A, Mwoga L, Shotorbani S, Holman D, Koup RA, Klasse PJ, Karlsson Hedestam GB, Tomaras GD, van Gils MJ, Montefiori DC, McDermott AB, Hyrien O, Moore JP, Wilson IA, Ward AB, Diemert DJ, de Bree GJ, Andrews SF, Caskey M, Sanders RW. Precise targeting of HIV broadly neutralizing antibody precursors in humans. Science 2025;389:adv5572. doi:10.1126/science.adv5572. https://doi.org/10.1126/science.adv5572
  12. Singh S, Kumar S, Luthra K. Recent advances in HIV-1 envelope-based vaccine designs for guiding broadly neutralizing antibody response. Journal of Virology 2026;100:e02202-25. doi:10.1128/jvi.02202-25. https://doi.org/10.1128/jvi.02202-25
  13. Varatharajan S, Krishnasai S, Girish C. Human immunodeficiency virus vaccines: Advances, challenges and future perspectives. World Journal of Virology 2026;15:116055. doi:10.5501/wjv.v15.i1.116055. https://doi.org/10.5501/wjv.v15.i1.116055
  14. Guenaga J, Ádori M, Bale S, Phulera S, Zygouras I, Schleich FA, Castro Dopico X, Agrawal S, Ota M, Wilson R, Cluff J, Dzvelaia T, Mandolesi M, Lee WH, Walsh AA, Melo MB, Verkoczy L, Irvine DJ, Corcoran M, Wilson IA, Carnathan D, Silvestri G, Ward AB, Ozorowski G, Karlsson Hedestam GB, Wyatt RT. Vaccination generates broadly cross-neutralizing antibodies to the HIV Env apex. Nature 2026;654:777-785. doi:10.1038/s41586-026-10429-3. https://doi.org/10.1038/s41586-026-10429-3
  15. Relano-Rodriguez I, Du J, Lin ZJ, Kerwin M, Tarquis-Medina M, Urbano E, Cui J, Watkins M, Lavine CL, Zhao P, Habib R, Agostino C, Ghosh S, Park J, Boroughs C, Walsh AA, Melo MB, Shukla N, Shaw GM, Hahn BH, Irvine DJ, Wells L, Weiner DB, Seaman MS, Kulp DW, Veazey RS, Pallesen J, Escolano A. Rapid elicitation of neutralizing Asn332-glycan-independent antibodies to the V3-glycan epitope of HIV-1 Env in nonhuman primates. Nature Immunology 2026;27:586-599. doi:10.1038/s41590-025-02408-z. https://doi.org/10.1038/s41590-025-02408-z
  16. Mishra N, Liang B, Roark RS, Ghosh AR, Callaghan S, Lee WH, Li X, Vo AL, Avillion G, Chowdhury RR, Habib R, Bibollet-Ruche F, Giese G, Oberoi P, Amereh K, Somanathan A, Zhu Y, Zhang Y, Kassab M, Tjio L, Andrabi S, Reyes RA, Allen JD, James NE, Randall KN, van der Maas L, Ben-Akiva E, Kacmarek-Michaels K, Plante S, Martella CL, Skelly AN, Singh A, Hurtado J, Dueker K, Capozzola T, Nedellec R, Ozorowski G, Lewis MG, Falcone S, Carfi A, Himansu S, Shapiro L, Crispin M, Hahn BH, Briney B, Irvine DJ, Burton DR, Ward AB, Batista FD, Kwong PD, Shaw GM, Andrabi R. Germline-targeting HIV immunogen induces cross-neutralizing antibodies in outbred macaques. Immunity 2026;59:1140-1160. doi:10.1016/j.immuni.2026.03.012. https://doi.org/10.1016/j.immuni.2026.03.012
  17. Skelly AN, Gristick HB, Li H, Gavor E, Connell AJ, Kreider EF, Marchitto L, Hogarty MP, Newby ML, Allen JD, Liu W, West AP, Ayyanathan K, Campion MS, Winters K, Gordon CG, Osbaldeston RA, Akeley MJ, Lewis E, Li Y, Singh A, Cruickshank K, Park Y, Zhao C, Li X, Amereh K, Van Itallie E, Carey JW, Albertus A, DeLaitsch AT, Keeffe JR, Lituchy MG, Walsh AA, Morris DJ, Habib R, Bibollet-Ruche F, Mishra N, Avillion G, Koranda NS, Plante SJ, Martella CL, Lora J, Wang EJD, Lewis MG, Martin MA, Nussenzweig MC, Seaman MS, Irvine DJ, Wiehe KJ, Haynes BF, Wagh K, Korber B, Andrabi R, Crispin M, Weissman D, Bjorkman PJ, Hahn BH, Shaw GM. Induction of broadly neutralizing HIV antibodies by a two-step mechanism informs vaccine design. Science 2026;392:aec6396. doi:10.1126/science.aec6396. https://doi.org/10.1126/science.aec6396
  18. Steichen JM, Madden PJ, Flynn CT, Phulera S, Shil M, Kalyuzhniy O, Liguori A, Kifude C, Sewall LM, Cottrell CA, Ma KM, Baboo S, Diedrich JK, McKenney K, deCamp AC, Carnathan DG, Phung I, Ramezani-Rad P, Marina-Zárate E, Freeman B, Xie Z, Lee JH, Sincomb T, Phelps N, Lu D, Goodwin D, Tingle R, Adachi Y, Alavi N, Tran J, Tran AS, Nascimento A, Sovie C, Bader DLV, Voic H, Zhou X, Pixton G, Walsh A, Melo MB, Schiffner T, Batista FD, Burton DR, Irvine DJ, Paulson JC, Yates JR, Ozorowski G, Ward AB, Silvestri G, Crotty S, Schief WR. Vaccination elicits HIV broadly neutralizing antibodies in primates. Nature 2026;656:723-733. doi:10.1038/s41586-026-10837-5. https://doi.org/10.1038/s41586-026-10837-5